Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Rating Reaffirmed by Benchmark

Anebulo Pharmaceuticals (NASDAQ:ANEB)‘s stock had its “speculative buy” rating reaffirmed by equities researchers at Benchmark in a report issued on Tuesday, Benzinga reports. They presently have a $8.00 price target on the stock. Benchmark’s target price would suggest a potential upside of 314.51% from the company’s current price.

Anebulo Pharmaceuticals Stock Down 5.9 %

Shares of Anebulo Pharmaceuticals stock opened at $1.93 on Tuesday. Anebulo Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.61. The company’s 50 day moving average is $2.04 and its 200 day moving average is $2.34. The company has a market cap of $50.05 million, a price-to-earnings ratio of -5.22 and a beta of -1.01.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.08. Sell-side analysts expect that Anebulo Pharmaceuticals will post -0.48 EPS for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.